Tirzepatide the FDA label directs initiation at 2.5 mg once weekly, with escalation in 2.5 mg steps at intervals of at least four weeks to a maximum of 15 mg weekly
L-
Over 10 injections from one vial, that wasted medication adds up to 30 to 70 units, or 0.15 to 0.35 ml at any concentration
The molecular stability of lipid-tailed GLP-1RAs, such as liraglutide and semaglutide, allows them to achieve active concentrations of 180350 pmol/L, while non-acylated agents like exenatide yield slightly lower levels (~ 50 pmol/L)
As more people initiate GLP-1 RAs for diverse indications, understanding these nuanced experiences will be key to improving adherence, minimizing harm, and optimizing outcomes
De Ritis G, Picardo S, Brancadoro D, and et al